A detailed history of Investment House LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Investment House LLC holds 860 shares of VRTX stock, worth $351,533. This represents 0.02% of its overall portfolio holdings.

Number of Shares
860
Previous 825 4.24%
Holding current value
$351,533
Previous $386,000 3.37%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$460.0 - $505.78 $16,100 - $17,702
35 Added 4.24%
860 $399,000
Q2 2024

Jul 22, 2024

BUY
$392.81 - $485.53 $56,957 - $70,401
145 Added 21.32%
825 $386,000
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $40,769 - $44,608
100 Added 17.24%
680 $284,000
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $182,363 - $204,107
580 New
580 $204,000
Q4 2021

Feb 09, 2022

SELL
$177.01 - $223.45 $1.91 Million - $2.41 Million
-10,795 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $904,410 - $1.01 Million
-4,986 Reduced 31.59%
10,795 $1.96 Million
Q2 2021

Jul 20, 2021

BUY
$187.49 - $221.1 $27,186 - $32,059
145 Added 0.93%
15,781 $3.18 Million
Q1 2021

May 06, 2021

BUY
$207.02 - $241.31 $132,492 - $154,438
640 Added 4.27%
15,636 $3.36 Million
Q4 2020

Jan 13, 2021

BUY
$207.01 - $276.09 $395,389 - $527,331
1,910 Added 14.6%
14,996 $3.54 Million
Q3 2020

Nov 06, 2020

BUY
$255.65 - $303.1 $314,449 - $372,813
1,230 Added 10.37%
13,086 $3.56 Million
Q2 2020

Jul 13, 2020

BUY
$225.48 - $295.8 $1.24 Million - $1.62 Million
5,480 Added 85.95%
11,856 $3.44 Million
Q1 2020

Apr 08, 2020

BUY
$199.77 - $247.81 $1.27 Million - $1.58 Million
6,376 New
6,376 $1.52 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Investment House LLC Portfolio

Follow Investment House LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Investment House LLC, based on Form 13F filings with the SEC.

News

Stay updated on Investment House LLC with notifications on news.